Hello, Welcome to Shine Consultant !
Conference Sponsor
400
2023 - 03 - 21
点击次数:
UBT251是联邦生物科技(珠海横琴)有限公司独立开发,具有完全自主知识产权的新药分子。近年来的研究表明,GLP-1、Glucagon和GIP通过其受体激动激动在能量代谢、糖代谢及脂肪代谢平衡中起着极其重要的作用。UBT251是一个新型三靶点多肽分子,可同时激动GLP-1受体、GIP受体和GCG受体。UBT251的临床前研究数据表明,该分子在相应的糖尿病、肥胖和NASH疾病动物模型中,如DIO小鼠、db/db小鼠、HFD+CCl4 诱导小鼠以及肥胖糖尿病食蟹猴,均表现出了强效的降糖、降脂和减重效应。并且在食蟹猴的药代试验数据也表明,该分子半衰期长,适于人体临床一周一次给药。我们已经完成UBT251的非临床研究,正在递交II型糖尿病、肥胖和NASH适应症的IND申请。我们相信,UBT251在降糖、减重、降脂、NASH治疗上具有潜在临床效益,是未来内分泌领域中的一个多靶点新药。现需求合作伙伴加快推进该药物的研发。
401
2023 - 08 - 23
点击次数:
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
402
2023 - 03 - 21
点击次数:
Professor Wu focuses on the development of new chemical drugs from anti-aging Chinese medicine as the main axis, and established AcaHealth Pharma. & Biotech. Company in 2009 in Incubation Center of National Yang-Ming University, then built up with three standard plant in Wu-gu Industrial Park, New Taipei City. After the EH-201 isolated from anti-aging herb, it was approved by the US FDA and TFDA INDand has completed six single-dose phase I clinical trial in the hospital affiliated to Taipei Medical University., and it was safe and secure by DSMB. The company has EH-201 global patents portfolio in indications including heart failure, anemia, chronic renal failure, dry eye, etc., and has also developed a global patent  portfolio for EH-201 derivatives.